Alder BioPharmaceuticals® submits BLA to FDA for eptinezumab
Alder BioPharmaceuticals announced it has submitted a BLA to the FDA for eptinezumab. Eptinezumab is an investigational monoclonal antibody for migraine prevention targeting the calcitonin gene-related peptide and is Alder’s lead commercial candidate. February 22, 2019